Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

29.57 +0.05 (+0.17%)

Streaming Delayed Price Updated: 1:15 PM EDT, Sep 17, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	944,305
Open	30.24
Bid (Size)	29.56 (200)
Ask (Size)	29.59 (100)
Prev. Close	29.52
Today's Range	29.55 - 30.54
52wk Range	22.96 - 43.15
Shares Outstanding	99,581,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗

Today 7:05 EDT

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Via The Motley Fool

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗

September 14, 2026

Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13...

Via MarketBeat

Performance

YTD	-16.5%	-16.5%
1 Month	-12.1%	-12.1%
3 Month	-2.4%	-2.4%
6 Month	-11.9%	-11.9%
1 Year	+24.8%	+24.8%

More News

Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗

September 11, 2026

Via The Motley Fool

Viking Therapeutics (NASDAQ:VKTX) Q2 Loss Beats Estimates, Shares Edge Lower as Obesity Pipeline Progresses ↗

July 29, 2026

Via Chartmill

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

Via The Motley Fool

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗

September 10, 2026

Via The Motley Fool

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗

September 05, 2026

Via The Motley Fool

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong ↗

September 03, 2026

Via The Motley Fool

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. ↗

August 30, 2026

Via The Motley Fool

Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? ↗

August 27, 2026

Via The Motley Fool

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

Via The Motley Fool

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗

August 08, 2026

Via The Motley Fool

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished ↗

August 06, 2026

Via The Motley Fool

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗

July 30, 2026

Via The Motley Fool

Viking Therapeutics Stock Moves Lower: What's Going On? ↗

July 30, 2026

Via Benzinga

Viking Therapeutics Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case ↗

July 28, 2026

Via The Motley Fool

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗

July 18, 2026

Via The Motley Fool

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." ↗

July 18, 2026

Via The Motley Fool

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

Via The Motley Fool

Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years ↗

July 10, 2026

Via Benzinga

Is This Biotech Stock a Buy After Its Massive Rally? ↗

July 09, 2026

Via The Motley Fool

Is It Too Late to Buy Eli Lilly? ↗

July 08, 2026

Via The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗

July 07, 2026

Via The Motley Fool

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?

Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Viking Therapeutics, Inc. - Common Stock trade on?

Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?

The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market

What is the current price of Viking Therapeutics, Inc. - Common Stock?

The current price of Viking Therapeutics, Inc. - Common Stock is 29.57

When was Viking Therapeutics, Inc. - Common Stock last traded?

The last trade of Viking Therapeutics, Inc. - Common Stock was at 09/17/26 01:15 PM ET

What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?

The market capitalization of Viking Therapeutics, Inc. - Common Stock is 2.94B

How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?

Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.